Table of Content - Chronic Obstructive Pulmonary Disease Market Report 2032 | MRFR

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation
Chronic obstructive pulmonary disease (COPD) Type Outlook (USD Billion, 2018-2030)

Emphysema

Chronic Bronchitis

Chronic obstructive pulmonary disease (COPD) Treatment Outlook (USD Billion, 2018-2030)

Drugs
- Bronchodilator Monotherapy
  - Short-Acting Beta2-Agonists (SABAs)
  - Long-Acting Beta2-Agonists (LABAs)
- Anti-Inflammatory Drugs
  - Oral And Inhaled Corticosteroids
  - Anti-Leukotrienes

Surgery
- Lung Volume Reduction Surgery (LVRS)
- Lung Transplant
- Bullectomy
- Others

Oxygen Therapy

Chronic obstructive pulmonary disease (COPD) End User Outlook (USD Billion, 2018-2030)

Hospitals & Clinics

Homecare Settings

Others

Chronic obstructive pulmonary disease (COPD) Regional Outlook (USD Billion, 2018-2030)

North America Outlook (USD Billion, 2018-2030)
- North America Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- North America Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- North America Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- US Outlook (USD Billion, 2018-2030)
- US Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- US Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- US Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Canada Outlook (USD Billion, 2018-2030)
- Canada Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Canada Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Canada Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others

Europe Outlook (USD Billion, 2018-2030)
- Europe Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Europe Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Europe Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Germany Outlook (USD Billion, 2018-2030)
- Germany Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Germany Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Germany Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- France Outlook (USD Billion, 2018-2030)
- France Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- France Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- France Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- UK Outlook (USD Billion, 2018-2030)
- UK Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- UK Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- UK Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Italy Outlook (USD Billion, 2018-2030)
- Italy North America Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Italy Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
      - Anti-Inflammatory Drugs
        
        Oral And Inhaled Corticosteroids
        
        Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Italy Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Spain Outlook (USD Billion, 2018-2030)
- Spain Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Spain Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Spain Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Rest Of Europe Outlook (USD Billion, 2018-2030)
- Rest Of Europe Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Rest of Europe Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
        
        Anti-Inflammatory Drugs
        
        Oral And Inhaled Corticosteroids
        
        Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Rest of Europe Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others

Asia-Pacific Outlook (USD Billion, 2018-2030)
- Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- China Outlook (USD Billion, 2018-2030)
- China Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- China Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- China Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Japan Outlook (USD Billion, 2018-2030)
- Japan Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Japan Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Japan Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- India Outlook (USD Billion, 2018-2030)
- India Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- India Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- India Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- South Korea Outlook (USD Billion, 2018-2030)
- South Korea Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- South Korea Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- South Korea Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Australia Outlook (USD Billion, 2018-2030)
- Australia Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Australia Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Australia Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
- Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others

Rest of the World Outlook (USD Billion, 2018-2030)
- Rest of the World Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Rest of the World Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Rest of the World Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Middle East Outlook (USD Billion, 2018-2030)
- Middle East Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Middle East Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Middle East Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Africa Outlook (USD Billion, 2018-2030)
- Africa Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Africa Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Africa Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others
- Latin America Outlook (USD Billion, 2018-2030)
- Latin America Chronic obstructive pulmonary disease (COPD) by Type
  - Emphysema
  - Chronic Bronchitis
- Latin America Chronic obstructive pulmonary disease (COPD) by Treatment
  - Metal Drugs
    - Bronchodilator Monotherapy
      - Short-Acting Beta2-Agonists (SABAs)
      - Long-Acting Beta2-Agonists (LABAs)
    - Anti-Inflammatory Drugs
      - Oral And Inhaled Corticosteroids
      - Anti-Leukotrienes
  - Surgery
    - Lung Volume Reduction Surgery (LVRS)
    - Lung Transplant
    - Bullectomy
    - Others
  - Oxygen Therapy
- Latin America Chronic obstructive pulmonary disease (COPD) by End User
  - Hospitals & Clinics
  - Homecare Settings
  - Others

Research Methodology on Global Chronic Obstructive Pulmonary Disease Market

1. Introduction:

Chronic obstructive pulmonary disease (COPD) refers to a group of chronic lung diseases that have an obstructed airflow from the lungs, including emphysema, chronic bronchitis and/or asthma. It is one of the main causes of morbidity and mortality worldwide and its increasing prevalence has led to a strong interest in research into this condition. This report presents a comprehensive overview of the latest findings in COPD and provides an understanding of the current market trends and emerging treatments. The objective of this research is to provide insights into the COPD market, by analysing the current treatments, and recent developments and assessing their future impact on the market.

2. Literature review:

This research involves a literature review of existing published research studies, reports and literature in the field of COPD, to identify and analyse current trends, developments and treatments available. Relevant databases such as Medline, PubMed, MedlinePlus and ScienceDirect are searched for relevant studies and reports. Relevant articles are carefully screened and those relevant to the research topic are selected based on their level of methodological rigour and relevance to the objectives of the research. Once the relevant articles are identified, the data from each study is collated, appraised and analysed for its relevance and accuracy.

3. Data Collection and Analysis:

The next step in this research is to collect primary data using a qualitative research approach. Semi-structured interviews are conducted with doctors and specialists, key opinion leaders, healthcare professionals and representatives of drug & device manufacturers, to understand their views on the current COPD landscape. In addition to this, patient/consumer surveys are carried out to gain insights into patient/consumer opinions and preferences when it comes to COPD treatments. The primary data collected from these interviews and surveys are analysed using thematic analysis and results are interpreted.

4. Secondary Data Collection and Analysis:

In addition to primary data collection, secondary data is collected from various sources such as WHO, CDC, peer-reviewed journals, and trade reports. This data is analysed to gain an understanding of the current global epidemiology and market trends. Data from the secondary sources are collated, analysed and interpreted.

5. Findings and Recommendations:

The results of both primary and secondary data collection and analysis are presented in a comprehensive report. This report provides an insightful overview of the COPD market, including current treatments, recent developments, trends and future outlook. Furthermore, detailed recommendations are provided to help stakeholders make informed decisions when it comes to developing and marketing new COPD treatments.

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE

6.1. Overview

6.2. Emphysema

Market Estimates & Forecast, by Region, 2020-2027